Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Tacrine–Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties

Tacrine–Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic,... Tacrine–melatonin hybrids are potential multifunctional drugs for Alzheimer's disease that may simultaneously palliate intellectual deficits and protect the brain against both β‐amyloid peptide and oxidative stress. Molecular modeling studies show that they target both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE. They are nontoxic and may be able to penetrate the CNS, according to in vitro PAMPA‐BBB assays. Tacrine–melatonin hybrids were designed and synthesized as new multifunctional drug candidates for Alzheimer's disease. These compounds may simultaneously palliate intellectual deficits and protect the brain against both β‐amyloid (Aβ) peptide and oxidative stress. They show improved cholinergic and antioxidant properties, and are more potent and selective inhibitors of human acetylcholinesterase (hAChE) than tacrine. They also capture free radicals better than melatonin. Molecular modeling studies show that these hybrids target both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE. At sub‐micromolar concentrations they efficiently displace the binding of propidium iodide from the PAS and could thus inhibit Aβ peptide aggregation promoted by AChE. Moreover, they also inhibit Aβ self‐aggregation and display neuroprotective properties in a human neuroblastoma line against cell death induced by various toxic insults, such as Aβ25–35, H2O2, and rotenone. Finally, they exhibit low toxicity and may be able to penetrate the central nervous system according to an in vitro parallel artificial membrane permeability assay for the blood–brain barrier (PAMPA‐BBB). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png ChemMedChem Wiley

Tacrine–Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties

Download PDF
14 pages

Loading next page...
 
/lp/wiley/tacrine-melatonin-hybrids-as-multifunctional-agents-for-alzheimer-s-NKKINIAOv6

References (93)

Publisher
Wiley
Copyright
Copyright © 2009 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim
ISSN
1860-7179
eISSN
1860-7187
DOI
10.1002/cmdc.200800414
pmid
19308922
Publisher site
See Article on Publisher Site

Abstract

Tacrine–melatonin hybrids are potential multifunctional drugs for Alzheimer's disease that may simultaneously palliate intellectual deficits and protect the brain against both β‐amyloid peptide and oxidative stress. Molecular modeling studies show that they target both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE. They are nontoxic and may be able to penetrate the CNS, according to in vitro PAMPA‐BBB assays. Tacrine–melatonin hybrids were designed and synthesized as new multifunctional drug candidates for Alzheimer's disease. These compounds may simultaneously palliate intellectual deficits and protect the brain against both β‐amyloid (Aβ) peptide and oxidative stress. They show improved cholinergic and antioxidant properties, and are more potent and selective inhibitors of human acetylcholinesterase (hAChE) than tacrine. They also capture free radicals better than melatonin. Molecular modeling studies show that these hybrids target both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE. At sub‐micromolar concentrations they efficiently displace the binding of propidium iodide from the PAS and could thus inhibit Aβ peptide aggregation promoted by AChE. Moreover, they also inhibit Aβ self‐aggregation and display neuroprotective properties in a human neuroblastoma line against cell death induced by various toxic insults, such as Aβ25–35, H2O2, and rotenone. Finally, they exhibit low toxicity and may be able to penetrate the central nervous system according to an in vitro parallel artificial membrane permeability assay for the blood–brain barrier (PAMPA‐BBB).

Journal

ChemMedChem – Wiley

Published: May 11, 2009

There are no references for this article.